NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) stockholders concerning the proposed merger of the company with BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).
Our investigation concerns whether Idera’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with BioCryst. Under the terms of the agreement, Idera stockholders will receive 0.20 shares of the combined company stock for each share of Idera common stock they own. On a proforma, fully diluted basis, Idera stockholders will own 48.4 percent of the combined company.
If you own Idera shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Idera Pharmaceuticals, Inc., please go to http://www.bespc.com/idera. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.